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Abstract
Cellular heterogeneity is an integral part of cancer development and progression. Progression can be associated with
emergence of cells that exhibit high phenotypic plasticity (including ‘‘de-differentiation’’ to primitive developmental states),
and aggressive behavioral properties (including high tumorigenic potentials). We observed that many biomarkers that are
used to identify Cancer Stem Cells (CSC) can label cell subsets in an advanced clinical stage of lung cancer (malignant
pleural effusions, or MPE). Thus, CSC-biomarkers may be useful for live sorting functionally distinct cell subsets from
individual tumors, which may enable investigators to hone in on the molecular basis for functional heterogeneity. We
demonstrate that the CD44hi (CD44-high) cancer cell subsets display higher clonal, colony forming potential than CD44lo
cells (n = 3) and are also tumorigenic (n = 2/2) when transplanted in mouse xenograft model. The CD44hi subsets express
different levels of embryonal (de-differentiation) markers or chromatin regulators. In archived lung cancer tissues, ALDH
markers co-localize more with CD44 in squamous cell carcinoma (n = 5/7) than Adeno Carcinoma (n = 1/12). MPE cancer cells
and a lung cancer cell line (NCI-H-2122) exhibit chromosomal abnormalities and 1p36 deletion (n = 3/3). Since miR-34a maps
to the 1p36 deletion site, low miR-34a expression levels were detected in these cells. The colony forming efficiency of
CD44hi cells, characteristic property of CSC, can be inhibited by mir-34a replacement in these samples. In addition the highly
tumorigenic CD44hi cells are enriched for cells in the G2 phase of cell cycle.
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Introduction
Tumor heterogeneity can be characterized by differential
expression of cell surface markers, genetic and epigenetic
differences, and/or differences in key signaling molecules or
effectors of cell function. Cellular heterogeneity can be character-
ized by differences in the functional (behavioral) properties of cells
(clonogenicity, colony formation ability in soft agar, tumorigenesis
etc.). Whereas many investigations have opted to associate cell
surface markers in tumor cells found at the primary tumor site
with CSC-behavioral properties, we observed that clinically
advanced stages are particularly enriched for cell subsets bearing
CSC-biomarkers. Thus, we postulated that advanced stage disease
does not prohibit (and may be advantageous) for associating
specific biomarkers with functional phenotypes. Accordingly, our
approach to biological discovery emphasizes designing appropriate
functional bioassays to characterize both the cell phenotypes and
molecular biology underlying tumor initiation, as well as tumor
progression.
Lung cancer is the leading cause of cancer mortality in both
men and women; with non small cell lung cancer (NSCLC)
accounting for 80–85% of cases [1]. For comprehending the
biology underlying this high mortality, we have selected an
advanced stage disease model (MPE). Lung cancer patients
presenting with MPE have significantly higher mortality than
those without MPE, or those who have cytologically negative
effusions [2–4]. Thus, the MPE-tumor burden is imbued with
biological properties that diminish survival of cancer patients.
Importantly, the MPE bulk tumor population is comprised of
heterogeneous subpopulations [5]. In part, this heterogeneity can
be characterized by biomarkers typically associated with features
of CSC (CD44, ALDH, cMET, CD166, MDR-1, uPAR, PTEN,
OCT-4, BMI-1, hTERT, SUZ12, EZH2).
An objective of the present study was to determine if we could
identify a tumor cell subset that displayed an increased compe-
tence for tumor propagation and maintenance, and to begin to
characterize the molecular bases for these properties. We first
studied CD44 as a selection marker for cells predicted to have high
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tumorigenic potential because it has previously identified CSC in
various epithelial cancers, including breast [6], head and neck,
[7,8], pancreatic [9,10], and prostate malignancies [11–15]. CD44
is highly expressed in different lung cancer subtypes, [16], and its
expression is related to poor prognosis in patients [17]. Recent
studies in NSCLC cell lines also characterize CD44hi cells as CSC
[16].
MPE-primary cultures contain a subpopulation of cells that
highly expresses CD44 (CD44hi). When these cells are sorted from
the MPE-primary cultures, they exhibit high tumorigenic poten-
tial, including engraftment of tumors in NOD/SCID IL2cRnull
mice in limiting dilutions of cell transplants. These properties are
characteristic of CSC. Fractions of CD44hi cells are associated
with an elevated expression of another CSC-marker associated
with xenobiotic metabolism, ALDH. The CD44hi/ALDHhi
phenotype is evident in both squamous cell (SCC) and adenocar-
cinoma (AC) of the lung, suggesting that similar marker profiles
may label behaviorally aggressive (highly tumorigenic) cell
fractions across the various ‘‘lineages’’ (histopathological subtypes)
of lung cancers [18].
MPE tumors commonly display hyperploidy and chromosomal
abnormalities. FISH analysis detected a common specific abnor-
mality in 1p36 region, suggesting that this region may play an
important role in contributing to aggressive behavioral properties.
The 1p36 region has previously been identified for containing the
locus that encodes tumor suppressor microRNA (miR-34a). Loss
of miR-34a expression is implicated in cancer progression [15,19];
this study adds to that evidence. Highly tumorigenic CD44hi cells
express low miR-34a, and miR-34a replacement inhibits colony
formation of CD44hi cells in soft agar. The cell cycle analysis of
CD44hi cells indicated that these highly tumorigenic cells reside in
the G2 phase of cell cycle.
Materials and Methods
Malignant Pleural Effusion (MPE) Collection, Processing
and Cell Culture
All subjects in the study underwent written informed consent by
a process approved by the institutional review board (IRB) at the
Veterans Affairs-Greater Los Angeles Healthcare System (VA-
GLAHS) and the study was approved by IRB-VAGLAHS. MPE
specimens (M-1, M-2 and M-3) were collected from patients at
Veterans Affairs-Greater Los Angeles Healthcare System (VA-
GLAHS). Cells are cultured in presence of 20–30% MPE (primary
culture medium or PCM) as described previously [5]. (Supporting
Information S1 and S2).
Control Established Cell Lines
Two established cell lines GM 05399 (normal fibroblast) and
H2122 (lung cancer) were used in the study. The fibroblast cell line
GM 05399 was obtained from the Coriell Institute for Medical
Research (Camden, NJ). The cell line was derived from a 1-year
old Caucasian male. The cell line is maintained in our laboratory
in Dulbecco’s Modified Eagle’s Medium (DMEM) in presence of
10% fetal bovine serum (FBS) [20]. The H2122 lung adenocar-
cinoma cell line was generated by Adi Gazdar from a malignant
pleural effusion, and acquired from Ilona Linnoila and Herb Oie
from the NCI. It was subsequently deposited into ATCC (NCI-
H2122 [H2122] ATCCH CRL-5985TM) [21]. The cell line is
maintained in our laboratory in RPMI-1640 medium in presence
of 10% FBS [22,23]. Both the cell lines are publicly available.
Antibodies
The following antibodies were used for flow cytometry FACS/
Sort: Mouse anti-Human IgG2b CD44-FITC, (BD Biosciences #
555478); FITC Mouse IgG2b k Isotype control, BD Biosciences #
555742); PE-labeled mouse anti-human CD44, (BD Pharmingen
# 555479); PE Mouse Mouse IgG2b k Isotype control, BD
Biosciences 555743. Anti-CD166-FITC (Mouse monoclonal;
IgG1 Setrotech # MCA 1926F, primary unlabeled anti-cMET
(mouse IgG2a, Abcam # 49210), anti-uPAR (mouse IgG, Santa
Cruz Biotech # 13522), Secondary antibody used for the study
used were: Goat (Fab’)2 anti-Mouse IgG (H+L)-PE-Cy.5.5 (Caltag
laboratories # M35018).
Immunohistochemistry (IHC)
Primary human lung cancer tissue (squamous cell carcinoma:
SCC and adenocarcinoma: AC) or human lung control tissue
(human normal alveolar and bronchiolar tissues) were obtained
from the UCLA Department of Pathology core facility. Xenograft
tumors derived from CD44hi cells injected in NOD/SCID
(IL2rcnull) mice were surgically removed, cut into 0.3–0.5 mm
pieces and fixed in ethanol (Fisher Scientific) or Z-fix (Anatech,
MI). For IHC, sections 3–5 m sections were cut and deparaffinized
and processed for antigen retrieval [5] and stained for marker
expression. Initially tissue sections were stained with single marker
antibody staining (CD44 or ALDH). Once the conditions were
optimized for single antigen staining then the dual antigen staining
(CD44 and ALDH) of tissue sections was achieved. Paraffin-
embedded tissue sections were deparaffinized and rehydrated.
After antigen retrieval (10 mM sodium citrate buffer, PH 6.0 by
steam 25 minutes) and blocking, endogenous peroxidases were
quenched (3% H2O2 in 1% sodium azide with PBS, 30 minutes in
room temperature). Slides were incubated with primary rabbit
polyclonal antibody to ALDH1A1 (Abcom Inc. Cat# ab51028),
overnight at 4uC. The slides were washed with PBS and incubated
with EnVision+ System-HRP Labelled Polymer Anti-Rabbit
(Dako Cat# K4003) for 30 minutes. The slides were incubated
in DAB (Vector Peroxidase Substrate Kit #SK-4100 with Nickel
Sol) for 10–20 minutes and then the slides were washed 5 minutes
3 times with PBS. For double staining with CD44 (R & D Systems,
mouse monoclonal IgG, Cat# BBA 10), slides were also incubated
in the primary antiserum at room temperature for 1 hour, followed
by the secondary antibody, Biotinylated-anti-mouse IgG (Vector
Cat# 9200), and then, ABC kit (Vector Cat# AK-5000) and
Vector Red Alkaline Phosphatase Substrate Kit I (Vector Cat#
SK-5100), developed for 20 minutes. Sections were counter-
stained with Harris’ hematoxylin, dehydrated in graded alcohol,
cleared in xylene and mounted on glass slides with cover slip. The
stained sections were examined under a microscope (Leica-Leitz
DMRBE or Olympus 1671) and positive or dual antigen
expressing areas determined by pathologists at UCLA.
Cytology and Flow Cytometry (FACS)
Photomicrographs were taken using the Leica- Leitz DMRBE
microscope mounted with a CCD camera and FACS analysis was
done using the Becton Dickinson FACSCalibur Analytic Flow
Cytometer [5]. Cell sorting was performed using the Becton
Dickinson FACSVantage SE Sorting Flow Cytometer at the
UCLA-JCCC Flow-cytometry core facility.
Reverse Transcriptase- PCR (RT-PCR) Analysis of Gene
Expression
The primary samples were first sorted into CD44hi and CD44lo
populations. The cells were collected and RNA was extracted
CD44 and Lung Cancer
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using Trizol and Fast Track 2.0 mRNA isolation kit (Invitrogen
Inc., Carlsbad, CA) and was reverse transcribed using RT kit [5].
The samples were used for PCR for the amplification of Bmi1,
hTERT, SUZ12, EZH2, and Oct4 genes. The following primers
were used: Bmi1 Forward - 59 AATCTAAGGAGGAGGTGA 39,
Reverse- 59 CAAACAAGAAGAGGTGGA 39, hTERT Forward -
59 GGAATTCTGGAGCTGCTTGGGAACCA 39, and Reverse-
59 CGTCTAGAGCCGGACACTCAGCCT-TCA 39, SUZ12
Forward -59 GATAAAAACAGGCGCTTA-CAGCTT 39, and
Reverse-59 AGGTCCCT-GAGAAAATGTTTCGA 39, EZH2
Forward- 59 TTGTTGGCGGAAGCGTGTAAAATC 39, and
Reverse -59 TCCCTAGTCCCGCGC-AATGAGC -39, and Oct4
Forward- 59 CAACTCCGATGGGGCCCT 39, and Reverse -59
CTTCAGGAGCTTGGCAAATTG 39. The conditions for am-
plifications of different genes have been described previously [5].
PCR products were separated by 8% gels (TBE, 50 mM Tris
borate pH 8.0, 1 mM EDTA) followed by Ethidium Bromide
staining. Gels were analyzed using the Kodak 1D software.
Colony Formation Efficiency Assay
In vitro colony-formation assays were done as described [12].
Sorted CD44hi and CD44lo cells were plated at clonal density
(100–500 cells/well) in six well tissue culture dishes in triplicates.
Holoclones with .20 cells were counted at the end of 10 days of
culture. The results are expressed as percentage cloning efficiency.
Spheroid Formation in Soft Agar Assay
Sorted CD44hi and CD44lo cells were plated at 1000 cells/well
in triplicates in six-well culture plates containing 0.35% top agar
layered over 0.5% base agar (DNA Grade) containing PCM.
Colonies were counted at 3 weeks post plating, results represent
mean from three independent experiments.
Tumorigenicity in NOD/SCID (IL2rcnull) Mice
All mice work related protocol for the study was approved by
the Institutional Animal Care and Use Committee at UCLA/
VAGLAHS. CD44hi and CD44lo cells were sorted by FACS and
injected at different cell doses (300/mouse, 3000/mouse and
30000/mouse) at the right and left flank respectively in NOD/
SCID (IL2cnull) mice in 100 ml of saline. Mice were monitored for
tumor growth at both the flanks. Results are represented as group
averages of tumor volume, as described [24].
miR-34a Transfection Studies
To analyze the effects that miR-34a has on colony formation
efficiency in soft agar assay the CD44hi cells were transiently
transfected with either miR-34a (AM17100, Applied Biosystem/
Ambion) or the negative control (scrambled) oligonucleotide.
Similarly CD44lo cells were transiently transfected with either anti-
miR-34a inhibitor (#AM17000, Applied Biosystem/Ambion) or
negative control anti-miR oligonucleotide (#AM17010, Applied
Biosystem/Ambion). The transfection was carried out with
CD44hi or CD44lo cells using Lipofectamin 2000 (Invitrogen) in
6 well plates with 50,000 cells/well with 100 pmol of miR, anti-
miR and control scrambled/oligonucleotides. After 2 days of
transfection the cells were collected and assayed for soft agar
colony forming efficiency as described above.
Fluorescent in situ Hybridization (FISH) Analysis of MPE
Samples
FISH studies were performed according to established protocol
[25]. LSI 1p36 probe was labeled with spectrum orange and LSI
1q25 probe was labeled with spectrum green and hybridized to
metaphase spreads as previously described [25,26]. Briefly,
metaphase spreads were prepared by standard cytogenetic
procedures. Labeled probes were hybridized and washes were
performed under identical conditions of stringency. Slides were
hybridized at 37uC overnight with 1–4 ng of the probe, 50%
formamide, 10% dextran, 26 SSC, and 50 ng Cot 1 DNA to
suppress repetitive sequences. Metaphase chromosomes were
counterstained with 4,6-diamidino 2-phenylindole (DAPI) in
Vectashield solution (Vector Laboratories Inc., Burlingame, CA).
Karyotyping of chromosomes were performed according to
established protocols.
Reverse Transcriptase- Quantitative PCR (RT-qPCR)
Detection of mir-34a in MPE Samples
Total RNA was isolated from samples using TRIzol. miR-34a
was measured by Step One Plus Real-time PCR system (Applied
Bio systems, CA) by using Taq-Man MicroRNA Assays (Applied
Biosystems, Foster City, CA) and normalized by RNU48 levels.
3 ul of 20 ng/ul of total RNA was used to perform Reverse
Transcriptase (RT) reaction (30 min at 16 deg, 30 min at 42 deg,
5 min at 85 deg) using 10 mM dNTPs, MultiscribeRT enzyme,
106RT buffer, RNase inhibitor, Taqman RT primer and water
in total reaction volume of 15 ul. For qPCR, 10 ul of 26Taqman
universal PCR master mix (No AmpErase UNG from ABI), 7 ul of
water, 1 ul of Taqman primer (miR-34a and RNU48) and 2 ul for
cDNA for each reaction was used, following amplification protocol
(10 min at 95 deg, 15 sec for 95 deg, 60 sec at 60deg for 40 cycles)
using Step One Plus Real-time PCR system (Applied Biosystems,
CA).
Surface Marker Labeling and Cell Cycle Analysis
Cells were stained with CD44-FITC and PI (Propidium Iodide)
for cell cycle analysis (modified from UCLA/Flow-cytometry core
facility protocol). Briefly, 16106 single cell suspension was washed
with PBS/2%PCM, pelleted, and labeled with mouse anti-Human
IgG2b CD44-FITC antibody (BD Biosciences # 555478) for
45 min. at room temperature in dark, control antibody was used
as negative control. The samples were re-suspended in 1 ml of
buffer containing 10 micrograms/ml of PI and 11.25 Kunitz units
of RNase and incubate for at least 30 min at 4uC in the dark and
analyzed on the flow cytometer within 30 min of PI staining.
Statistical Analysis
Data are represented as mean6SD and were analyzed with
two-sided t test by EXCEL and repeated measures analysis of
variance (ANOVA) was used for comparison among groups by
SAS 9.3. A P value,0.05 was considered statistically significant.
Results
CD44 Expression Profile of MPE Derived Tumor Cells
MPE-tumor cells can be isolated and expanded in short term
primary cultures in presence of MPE fluid and autologous non-
tumor cells [5]. Heterogeneous populations, including candidate
CSC, are present in the MPE- tumor population, as reflected by
the variable expression of CSC-biomarkers: c-MET, uPAR,
MDR1, CD166, CD44, and ALDH. Thus, in addition to
intratumoral morphological heterogeneity, there are differences
in the surface CD44 labeling intensities, and these differences can
be exploited to segregate cell subsets [5].
The primary cultures from three different MPE-samples (M-1,
M-2 and M-3), contain morphological variants (flat, oval and
rounded shapes) by light microscopy (Figure 1A, B). By the 4th
week of culture, the adherent tumor cells display a more
CD44 and Lung Cancer
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homogeneous morphology pattern in culture (Figure 1C). Cul-
tured cells uniformly express CD44 in all three tumor samples
(Figure 1D), but the labeling intensity is highly variable both
between and within the same sample. Thus, compared to cells
labeled with secondary antibody alone, the samples are 96%, 99%
and 98% positive for CD44; however, the Mean Fluorescence
Intensities (MFIs) of CD44 labeling are 10861, 5295 and 2120
respectively. Thus, the surface labeling intensity of CD44
expression may vary from 2 to 5 fold among tumor samples,
and there is typically a large variance in average surface CD44
labeling within individual samples.
Absence of Morphological Differences between CD44hi
and CD44lo Cells
MPE-primary cultures acquire a more homogenous morpho-
logical pattern of growth over time. To determine if subtle
differences in culture morphology could distinguish the CD44hi
from CD44lo cultures, the M-1, M-2 and M-3 samples were
labeled with anti-CD44 antibody and sorted by FACS, with gates
set at 5% of cells at the high CD44 marker and low CD44 marker
expression (Fig. 1E). The purity of the CD44hi and CD44lo cells
were $98%, as revealed by post sort analysis (data not shown).
The sorted cells CD44hi (Figure 1F) and CD44lo (Figure 1G) were
washed and plated out in PCM for 2–3 days to evaluate their
morphological differences. These studies suggest that there is no
distinguishing difference in culture morphology associated with
surface CD44 expression.
CD44hi Cells show High Colony Forming Ability
To investigate whether the CD44hi cells are functionally
different from the CD44lo cells in colony forming efficiency, we
sorted and cultured these subsets from the three samples (M-1, M-
2 and M-3). 100–500 cells of CD44hi or CD44lo cells were plated
in individual wells of 12-well plates. Although we are unable to
detect significant differences in initial plating efficiency, but we do
observe that CD44hi cells are more competent at forming
holoclones than the CD44lo cells (t test and ANOVA: P,0.05)
(Figure 2A). Thus, an intrinsic biological difference between
CD44hi and CD44lo cells seems to an inherent differential
competency in forming holoclones.
CD44hi Cells show High Spheroid Forming Ability in Soft
Agar Cultures
Another surrogate measure commonly used to characterize
CSC is a differential competency at forming ‘‘anchorage
independent’’ colonies in soft agar [12]. CD44hi and CD44lo cells
from samples (M-A-1, M-10-26 and M-8-15) were evaluated by
plating the sorted cells in agarose supplemented with PCM. The
CD44hi cells from all three samples uniformly exhibit higher
spheroid formation efficiency than the CD44lo cells (t test and
ANOVA: P,0.05) (Figure 2B). The more robust CD44hi colonies
are also qualitatively distinguishable from vestigial colonies formed
by CD44lo cells (Figure 2C versus 2D). Thus, CD44hi cells possess
greater competency at forming colonies in soft agar than the
CD44lo cells derived from the same lung cancer biospecimen.
Figure 1. Morphologically variant cells in MPE samples and absence of morphological changes between CD44hi and CD44lo cells.
The tumor cells from M-1, M-2 and M-3. (A) 1006 (2–3 weeks). (B) 4006 (2–3 weeks). (C) Later stages of culture 1006 (6–10 weeks). (D) CD44- FACS
expression pattern and MFI. (E) Sorting of CD44hi and CD44lo cells (5–10%). The sorted cells CD44hi and CD44lo were washed and plated out in PCM
for 2–3 days to evaluate their morphological differences. (F) Morphology of sorted CD44hi cells and sorted (G) CD44lo cells were similar (1006). The
purity of the CD44hi and CD44lo cells were $98%, as revealed by post sort analysis (data not shown).
doi:10.1371/journal.pone.0073195.g001
CD44 and Lung Cancer
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CD44hi Cells Variably Display Molecular Features that
Characterize CSC
Markers that characterize candidate CSC (hTERT, SUZ12,
OCT-4 expression etc.) are evident in cell pellets isolated from the
MPE samples [5]; thus, CSC are a likely component of the MPE-
tumor mix. Such CSC markers are variably comprised of
embryonal or polycomb protein components and their expression
may predict the labeling of cell subsets that possess high
tumorigenic or colony forming potentials [27]. To determine if
these candidate CSC markers were limited to specific CD44 sorted
subsets, we screened the CD44hi and CD44lo cell subsets for
differential mRNA expression; RT-PCR amplification of BMI-1,
hTERT, SUZ-12, EZH2 and OCT4 was performed. Indexed to
beta-tubulin mRNA, there is a marked variability in the expression
of these markers within the CD44-sorted cell subsets (Figure 2E).
For example, BMI-1 and hTERT mRNA is more highly expressed
in CD44hi cells than the CD44lo cells in sample M-3 and M-2
respectively. Only in sample M-1, expected distributions of CSC
markers (high BMI, hTERT, SUZ12, EZH2 and OCT-4) are
evident in CD44hi cells than the CD44lo cells.
These results indicate that 1) molecular markers that encode for
modifiers of chromatin structure or embryonal genes may be
present in both highly tumorigenic and non-tumorigenic subsets of
individual lung cancer cell populations, and 2) that there is marked
variability in the differential expression of these candidate ‘‘CSC-
biomarkers’’ in lung cancer biospecimens.
Figure 2. Higher clonal efficiency and colony forming potential of CD44hi cells and their CSC molecular markers expression in
comparison to CD44lo cells. The sorted cells CD44hi and CD44lo from MPE samples were analyzed in triplicates for their (A) clonal efficiency
(Sample M-1: colonies CD44hi = 35.8 (SD= 5.04) vs CD44lo = 21.7 (SD=6.2) (P = 0.03); Sample M-2 colonies CD44hi = 59.8 (SD= 3.2) vs CD44lo = 40.6
(SD= 4.1) (P = 0.003); Sample M-3 colonies CD44hi = 53.4 (SD= 5.3) vs CD44lo = 33.9 (SD= 3.6) (P = 0.006)); The mean effect of CD44hi versus CD44lo is
17.6 (95% CI: 8.31, 26.89: p = 0.015). (B) colony forming ability in soft agar. (Sample M-1: colonies CD44hi = 16.6 (SD=1.1) vs CD44lo = 8 (SD= 1.1)
(P = 0.0006); Sample M-2: colonies CD44hi = 27 (SD= 7) vs CD44lo = 12 (SD= 3) (P = 0.02); Sample M-3: colonies CD44hi = 24.3 (SD= 6.1) vs CD44lo = 12.6
(SD= 2.5) (P = 0.03)). The mean effect of CD44hi versus CD44lo is 11.8 (95% CI: 3.41, 20.14; P = 0.026). Columns, mean from three independent
experiment; SD, *, P,0.001, compared with the CD44lo groups, (student’s t test). (C) Soft agar colonies derived from CD44hi cells (1006) and (D)
CD44lo cells (1006). (E) Expression profile of BMI-1, hTERT, SUZ12, EZH2 and OCT-4 in sorted CD44hi and CD44lo cells were analyzed by reverse
transcriptase-qPCR. In sample M-3 only BMI-1 is expressed at high level in CD44hi population than the CD44lo cell population. In sample M-2 slight
higher expression of hTERT in CD44hi cells than CD44lo cells. The CD44hi population of sample M-1 expressed high level of BMI-1, hTERT, SUZ12, EZH2
and OCT-4, than CD44lo population.
doi:10.1371/journal.pone.0073195.g002
CD44 and Lung Cancer
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e73195
CD44hi Cells form Tumors in NOD/SCID (IL2rcnull) Mice
As specific molecular markers cannot reliably differentiate
tumorigenic from non-tumorigenic cell subsets, can we distinguish
these subsets on the basis of behavioral phenotypes? The CD44hi
and CD44lo cell subsets from individual tumor cell populations
consistently display differences in adherent holoclone and soft agar
colony formation. A key experimental measure of ‘‘CSC’’,
however, is by the demonstration of higher tumorigenic potential
in mouse models. It has been shown that NOD/SCID(IL2rcnull
mice are sensitive model to evaluate for highly tumorigenic CSC-
behavioral phenotypes [16,28]. To corroborate observed differ-
ences in colony forming and spheroid forming abilities of CD44hi
vs CD44lo cells with in vivo tumorigenesis, we investigated their
ability to form tumors in NOD/SCID (IL2rcnull) mice.
Limiting dilutions (30,000; 3,000; 300) of sorted CD44hi and
CD44lo cells from M-1 and M-2 MPEs were injected into the right
and left flanks respectively of NOD/SCID (IL2rcnull) mice.
CD44hi tumor cells of the M-1 sample formed tumors in 3/3
mice at both 30,000 and 3,000 injected cell doses, and in one of 3
mice injected with 300 tumor cells (Figure 3 A, B, C). The latency
period of tumors was 50–90 days, 90–150 days and 150 days, for
30,000; 3,000 and 300 CD44hi cells respectively (Figure 3E). Thus,
the kinetics of tumor formation by the highly tumorigenic CD44hi
cells was dose-dependent. The CD44hi tumor cells from sample
M-2 generated tumors in 2 of 3 mice at 30,000 tumor cells with a
latency period of 90–100 days, a higher latency period than
observed in CD44hi cells of sample M-1 (Figure 3E). Thus,
although CD44hi cells consistently display higher tumorigenic
potentials than CD44lo cells of the same specimen, individual
tumor specimens may display different growth kinetics in the
evaluation of CSC properties in behavioral bioassays.
Notably, the CD44lo cells from either primary culture did not
form tumors in the left flanks of the mice during the entire
monitoring interval (Fig. 3 B and E). Moreover, we also did not
observe tumor formation with the injection of 56105 unsorted cells,
even though this population presumably contained ,5–10% (or
25,000–50,000) CD44hi cells. This interesting observation suggests
that CD44hi cells may be exposed to inhibitory influences towards
tumor growth by cells that have a lower intensity surface CD44
expression in the same tumor population.
To test whether implanted CD44hi cells contributed to
heterogeneous tumors (suggestive of multipotent differentiation),
engrafted tumors generated from CD44hi from M-1 cells were
extirpated, digested, and cell surface marker analysis was
performed by FACS on single cell suspensions. The tumor cells
remained highly positive for the CD44 marker, with 98.2% of cells
staining positive, although the CD44-MFI was even higher than
the originally implanted cells. Heterogeneity amongst cells was
evidenced by the variable expression of other commonly
associated CSC biomarkers (Figure 3D), [cMET (40.4%), uPAR
(47.6%) and CD166 (27.4%)]. Cells bearing these markers were
also previously detected in the primary MPE biospecimen samples,
at varying fractions [5]. Together, these results indicate that
CD44hi cells derived from MPE are not only more tumorigenic
than the CD44lo cells, but that the CD44hi cells are also capable of
generating tumors with heterogeneous marker profiles, similar to
those found in the primary MPE samples.
CD44 and ALDH Expression in Implanted Xenografts
Resemble Expression of these Markers in Archived
Human Lung Cancer Pathology Specimens
CD44hi cells in MPE primary cultures contain cell fractions with
high ALDH expression (i.e., the CD44hi/ALDHhi surface
phenotype) [5]. We extend that observation to prospectively
collected biospecimens. Using immunohistochemistry, we observe
variable expression of CD44 and ALDH markers in the mouse
xenograft tumors generated from CD44hi cells. Pathological and
marker expression patterns in xenografts compare favorably to
archived human lung cancer, and to tumor-adjacent human
normal alveolar and normal human bronchiolar tissues. H&E
sections of M-1 and M-2 CD44hi xenografts (Figure 4 A–H)
corroborate the original pathological diagnoses of large cell lung
cancer and lung SCC respectively (Figure 4 I–N). Consistent with
flow cytometry data, CD44 labeling is evident on the majority of
cells. However, intra-tumoral variation of CD44 expression is
clearly evident (Figure 4 B, F), again consistent with the flow
cytometry profile. Similarly when the xenograft sections are
labeled for ALDH expression, some cells show higher expression
than other tumor cell populations (Figure 4 C, G). When co-
expression of CD44 and ALDH is examined by dual marker
staining of xenograft tumor sections, there is tumor to tumor
variability in the co-localization of these markers (Figure 4 D, H).
These labeling patterns are representative of resected human
pathology specimens, as evidenced by the morphology and
immunohistopathology expression patterns observed in archived
samples (Figure 4 I–J and L–M), which show CD44 (Figure 4 J, L),
ALDH (Figure 4 K, M) and dual staining expression pattern of
CD44 and ALDH (Figure 4 N). Arrows in the figure point to high
expression of respective markers in SCC tissue sections (Figure 4
J–M). Dual expression of CD44 and ALDH in SCC tissue sections
may be more intense toward the center of tumor nodules (Figure 4
N).
To determine if such labeling was restricted to the neoplastic
tissue, tumor adjacent normal lung alveolar (Figure 4 O–Q) and
bronchiolar (Figure 4 R–T) tissues were also examined. The
photomicrographs suggest that high expression of ALDH (Figure 4
P), and co-expression ALDH and CD44 (Figure 4 Q) is evident in
histologically normal alveolar tissues as well, where representative
H& E photomicrographs of normal bronchiolar tissue shows the
characteristic presence of ciliated and goblet cells (Figure 4 R).
Foci of ciliated and goblet cells highly express CD44 or both CD44
and ALDH in this anatomical location (Figure 4 S, T). Since
CD44 and ALDH markers are also co- expressed in normal lung
tissues, the presence of these markers per se may not distinguish
neoplastic from non-neoplastic tissues.
To determine if we could identify a relationship between
CD44/ALDH expression and histopathological subtypes of lung
cancer, tissue sections were evaluated for CD44, ALDH and co
expression of CD44 and ALDH. CD44 and ALDH are commonly
expressed in all lung tumor samples, both with respect to fractions
of cell labeling, and intensity of labeling (Table 1). The data
suggest that SCC express higher levels (4+/3+) of CD44 and
ALDH than adenocarcinoma, and co localization of these markers
(the CD44hi/ALDHhi surface phenotype) is also easier to identify
in SCC (n= 5/7) than in adenocarcinoma (n= 1/12).
Rearrangement of Chromosome 1p36 and Reduced
Expression of miR-34a in CD44hi Cells
Abnormal chromosomal numbers, and both hyper- and
aneuploidy are common in lung cancer. It is not clear whether
such chromosomal changes are associated with the tumorigenic
potential of cancer cells. To investigate a possible association,
karyotype analysis was performed on the three MPE samples.
Normal fibroblast GM 05399 and the lung cancer cell line NCI-
H2122 were used as controls to represent non tumorigenic and
immortalized tumor cell models [20–23]. All three MPE samples
M-1, M-2 and M-3 showed extensive chromosomal changes with
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hyperdiploid number of chromosomes 83, 67, and 74 respectively
(Figure 5B, D, F). Meanwhile, the normal fibroblast contained 46
chromosomes; the cell line NCI-H2122 contained 58 chromo-
somes (Figure 5H). MPE cells uniformly contained translocations
and deletions, and rearrangements at chromosomal region 1p, a
common site of rearrangements seen in lung cancers. A FISH
analysis was carried out using a 1p36 (orange) probe and a control
1q25 (green) probe to detect specific 1p changes (Figure 5A).
Sample M-1 has 3 copies of chromosome 1 (q), of which 2 copies
(D) are rearranged at 1p and 1q (Figure 5C). The sample M-2
exhibits 4 Chromosome 1 (q) (3 with intact 1p/1q and 1 with 1p
deletion (D)) (Figure 5 E). The third sample M-3 has 2 copies of 1p
(D) and 6 (q) copies of 1q (consistent with 1p deletion) (Figure 5E).
The immortalized MPE-derived lung cancer cell line (NCI-
H2122) also displays an abnormal karyotype with hyperploidy
(Figure 5H). NCI-H2122 has 2 copies (qand D) of 1p/1q but one
1p is rearranged with additional material of unknown origin at 1p
terminal region (D) (Figure 5I). By contrast, the normal diploid
human fibroblast GM 05399 cells show normal distribution of two
copies of 1p/1q (q) (Figure 5J).
Thus, we detected Loss of Heterozygosity (LOH) at 1p36 in two
MPE samples and rearrangements of both 1p/1q regions in the
third MPE sample. Cell line H-2122 contained one normal
chromosome 1 and unbalanced translocation of unknown origin at
1p36 consistent with deletion of 1p. The observations suggested
that 1p36 deletion could result in the inactivation of a tumor
suppressor gene. A bioinformatics search identified candidates,
including the code for miR-34a that mapped to this locus.
Since expression of miR-34a may contribute to the different
biological properties of CD44hi versus CD44lo cells in individual
tumors, we evaluated its expression levels in CD44hi, CD44lo and
unsorted total cell populations in fractionated MPE-biospecimens
(Figure 6A). The expression of small nucleolar RNA-RNU48 was
used as a reference for gene expression in this assay (data not
shown), and miR-34a results were normalized with the RNU48
expression. Although the expression of the small nucleolar RNA-
RNU48 may itself be dysregulated in cancer [29], our study
demonstrated a similar basal expression pattern across the sample
sets. On RT-qPCR analyses, however, there was no significant
difference in miR-34a expression in the CD44hi and CD44lo
subsets of the MPE sample M-2; the expression in this sample was
similar to that of the control fibroblasts. In contrast, CD44hi cells
have significantly lower level of miR-34a than the CD44lo cells in
sample M-1, as well as in the immortalized cell line NCI-H2122.
Figure 3. Tumorigenicity of CD44hi population from primary tumor cells in NOD/SCID (IL2rcnull) mice. (A) Tumorigenicity and latency
period of CD44hi cells (M–1) injected with at 30,000; 3,000 and 300 cells. Mice injected with CD44hi (right flank) formed tumors and CD44lo cells did
not form tumor (left flank). The numbers (1/3, 2/3 or 3/3) represent number of animals with tumor/group at particular time point of measurement.
Time period of days after tumor implantation is expressed along X axis and tumor growth volume is expressed as mm3 along Y axis. Unsorted
parental primary tumors implanted with 500,000 cell/mice did not show any tumor growth even after 3 months of tumor cell implantation (data not
shown) (B) Mice bearing tumors on the right flank injected with CD44hi cells and no tumor was detected at the left flank injected with CD44lo cells (C)
Resected tumors formed by CD44hi cells in mice. (D) FACS analysis of single cells obtained from mouse tumors derived from CD44hi cells of M-1 MPE
sample. The tumor cells show expression of CD44, cMET, uPAR and CD166 markers. (E) Tumorigenicity and latency period of CD44hi and CD44lo cells
of samples M-1 and M-2 in NOD/SCID (IL2rcnull) mice.
doi:10.1371/journal.pone.0073195.g003
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These data suggest that loss of miR34a may contribute to
aggressive biological properties and high tumorigenic potentials in
some lung cancers.
Figure 4. Immunohistological study of tumors generated by CD44hi cell population in mouse, human squamous cell carcinomas
(SCCs), human alveolar and human bronchiolar tissues. The photomicrograph A, B, C and D represent the tumors derived from Sample M-1
and E, F, G and H represent tumor derived from sample M-2 in NOD/SCID (IL2rcnull) mice. The following stains are represented: H&E staining (A and E),
immunohistochemistry for CD44 expression (B and F), ALDH expression pattern (C and G) and the immunohistochemistry for dual CD44 and ALDH
staining (D and H). Representative human two lung squamous cell carcinoma (SCC) tissue samples (I, J, K and L, M, N) were stained by H&E (I), CD44 (J
and L), ALDH (K and M) and immunohistochemical staining for dual markers CD44 and ALDH (N). Human alveolar tissue sections were stained for
CD44 (O), ALDH (P) and dual markers CD44 and ALDH (Q). Human-bronchiolar tissue sample was stained for CD44(R), ALDH (S) and dual markers
CD44 and ALDH (T).
doi:10.1371/journal.pone.0073195.g004
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Soft Agar Colony Formation by CD44hi Cells is Correlated
with the Decreased Expression of miR- 34a in Individual
Lung Cancers
To determine whether the decreased expression of miR-34a
could be directly associated with an aggressive phenotype in some
lung cancers, we compared colony forming ability and tumori-
genic potentials of CD44hi tumor cells with their miR-34a
expression. The loss of miR-34a in these samples directly
correlated with a competency at high colony formation. Thus,
CD44hi cells with the lowest miR-34a expression formed a higher
number and larger colonies, while CD44lo cells with higher miR-
34a expression formed smaller number of vestigial colonies
(Figure 2). Fibroblasts, with high miR-34a expression, failed to
form colonies in soft agar (data not shown).
To further assess the role of miR-34a towards mediating a
biological effect in tumor cells subsets, CD44hi and CD44lo cell
populations were transfected with miR-34a or anti-miR-34a, and
colony formation was assayed. Introduction of miR-34a into
CD44hi cells resulted in 80–95% reduction of soft agar colonies (t
test: P = 0.01–0.002) (Figure 6B, C). As expected, introduction of
anti-miR-34a into CD44lo led to increased number of soft agar
colonies (t test: P = 0.04–0.01) (Figure 6D, E). The results were
significant by t test analysis as indicated in Figure 6B and 6D.
Though the differences were significant, however, by ANOVA test
the P values were 0.112 (Figure 6B) and 0.125 (Figure 6D),
indicating that either the variability within the two samples were
greater or the sample numbers were few to be significant by
ANOVA analysis. However, miR-34a clearly plays an important
role in tumor growth suppression; the loss of miR-34a expression is
Table 1. CD44 and ALDH expression pattern in Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AC) of the lung.
Case Tumor Type Grade CD44 Staining ALDH Staining Co-localization
Amount Intensity Amount Intensity
S-46 SCC 3+ 4+ 3+ 1+ 1+ Y
S-44 SCC 2+ 1+ 3+ 2+ 2+ Y
1–57 SCC 3+ 4+ 3+ 3+ 2+ Y
S-24 SCC 3+ 4+ 3+ 4+ 3+ Y
S-34 SCC 3+ 4+ 3+ 1+ 1+ Y
1-2T SCC 3+ 0+ 0+ 1+ 2+ NA
1–76 SCC 2+ 4+ 3+ 0+ 0+ NA
9–69 AC 3+ 0+ 0+ 0+ 0+ NA
1–68 AC 2+ 0+ 0+ 0+ 0+ NA
8–94 AC 3+ 1+ 3+ 0+ 0+ NA
S-06 AC 1+ 4+ 3+ 0+ 0+ NA
1–70 AC 2+ 0+ 0+ 2+ 2+ NA
1-2T AC 1+ 0+ 0+ 0+ 0+ NA
1-08 AC 3+ 0+ 0+ 3+ 3+ NA
S-57 AC 2+ 2+ 3+ 0+ 0+ NA
S-42 AC 1+ 0+ 0+ 0+ 0+ NA
1–18 AC 3+ 0+ 0+ 0+ 0+ NA
9–79 AC 2+ 1+ 2+ 2+ 2+ N
S-35 AC 1+ 4+ 3+ 1+ 1+ Y
Tumor Type
SCC= Squamous cell carcinoma
AC=Adenocarcinoma.
Grade
1+=Well differentiated
2+=Moderately differentiated
3+= Poorly differentiated.
Amount of Staining
0+=,5% of cells
1+ = 6 to 24% of cells
2+ = 25 to 49% of cells
3+ = 50 to 74% of cells
4+ = 75% or greater of cells.
Intensity of Staining
0+=no staining
1+=weekly positive
2+=moderately positive
3+= strongly positive.
Co-localization
N=No co-localization
Y = co-localization identified
NA=Not Applicable.
doi:10.1371/journal.pone.0073195.t001
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evident in aggressive (CD44hi subsets) of individual cancers, and
this loss directly contributes to the development of a highly
tumorigenic phenotype.
CD44hi Cells Display Extended G2 Phase Cell Cycle
It is believed that CSCs remain in quiescent state and cycle
slower through the cell cycle; these are properties resembling
Figure 5. Karyotype and Fluroscent In Situ Hybridization (FISH) analysis of MPE derived tumor cells. (A) Dual color FISH analysis was
done using 1p36 and 1q25 (control) probes. Representative position of the probe 1p36 (orange) and 1q25 (green) on chromosome 1. (B) Sample M-1:
Abnormal hyperdiploid karyotype (83 chromosomes) and (C) with 3 copies of chromosome 1 (q) but have 2 copies (D) of rearranged 1p and 1q. (D)
Sample M-2: Abnormal hyperdiploid karyotype (67 chromosomes) and (E) with 4 Chromsome 1 s (q) (3 with intact 1p/1q and 1 with 1p deletion (D)).
(F) Sample M-3: Abnormal hyperdiploid karyotype (74 chromosomes) and (G) with 2 copies of 1p (D) and 6 (q) copies of 1q (consistent with 1p
deletion). (H) Sample NCI-H2122 Abnormal karyotype (58 chromosomes) and (I) with 2 copies (qand D) of 1p/1q but one 1p is rearranged with
additional material of unknown origin at 1p terminal region (D). (J) Normal deployed human fibroblast cell line GM 05399 control with two copies of
1p/1q (q).
doi:10.1371/journal.pone.0073195.g005
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Figure 6. Expression of miR-34a in CD44hi and CD44lo cells evaluated by RT-qPCR and exogenous delivery of miR-34a into CD44hi
cells inhibits colony formation and anti- miR-34a into CD44lo cells increases colony formation. (A) miR-34a expression in unsorted,
CD44hi and CD44lo cells of two primary samples (M-1 and M-2), established NSCLC cell line NCI-H-2122 and normal human fibroblast cell line GM
05399. The miR-34a expression has been normalized with RNU48. (B) Sorted CD44hi cells (samples M-1 and M-2) when transduced with miR-34a show
decreased colony forming efficiency in comparison to miR-control transduced CD44hi tumor cells; (Sample M-1: miR control = 131.6 (SD= 30.5),+miR-
34a = 7 (SD=2.6) and P= 0.002; Sample M-2: miR control = 75 (SD=19.6),+miR-34a= 23 (SD= 5.5) and P= 0.01); The mean effect with miR-34a versus
miR-control on CD44hi cells is 288.3 (95% CI: 2288.12, 111.45; P = 0.112) (C) Sorted CD44hi tumor cells transduced with miR-34a exhibit small colony
size (bottom panel) than miR-control transduced CD44hi tumor cells (upper panel); (D) The CD44lo cells from Sample M-1 and M-2 transduced with
anti-miR34a show increased colony forming efficiency than tumor cells transduced with miR-control; (Sample M-1: miR control = 21 (SD= 4.5),+anti-
miR-34a= 33 (SD= 5.2) and P= 0.04; Sample M-2: miR control = 24.6 (SD= 4.1),+anti-miR-34a = 39.3 (SD=5.1) and P= 0.018); The mean effect with
anti-miR-34a versus miR-control on CD44lo cells is 213.3 (95% CI: 220.43, 47.10; P = 0.125). (E) Sorted CD44lo cells transduced with anti-miR-34a
exhibit bigger colony size (bottom panel) than miR-control transduced tumor cells (upper panel).
doi:10.1371/journal.pone.0073195.g006
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normal stem cells [30]. We evaluated the cell cycle phase of the
CD44hi cells that show higher tumorigenic potential by FACS.
Samples (A) M-1, (B) M-2 and (C) M-3 were stained for CD44
and PI and then first gated with PI staining pattern (Figure 7i) and
then back-gated for CD44 (CD44-FITC/FL-1) and PI (FL-2A)
(Figure 7ii). The panels iii, iv and v of figure 7 represent histogram
of cell cycle stages of CD44hi and CD44lo gated cells (5–10% of
total cells) and un-gated total cell population respectively.
Figure 7D represents the population at different cell cycle stages
G1 (M1), G2 (M2) and S (M3) stages. The CD44hi cells of sample
(A) M-1 shows that S and G2 phases are 15.75% and 72.61% of
the gated cell population respectively (Figure 7A iii). CD44lo cells
of the same sample represent 4.36% (S) and 1.81% (G2) of gated
cell population (Figure 7A iv). Thus CD44hi cells are enriched 40-
fold for cells in the G2 phase than the CD44lo cells.
Similarly, sample (B) M-2 analysis indicates that CD44hi cells in
S/G2 phase are higher (12.03/32.19) than the CD44lo cells (S/
G2:5.18/7.14) (Figure 7B iii and iv and D). In this sample, the
CD44hi cells are enriched for cells in S/G2 phase at 2.3/4.5 times
higher than CD44lo cells. In the third sample (C), M-3, cells in S/
G2 phase represent 6.25/15.17 percent of the whole population,
where CD44lo cells in the as S/G2 represent 3.37/3.32
respectively (Figure 7C ii and iii and D). The gated CD44hi cells
at S/G2 cell cycle stages are 1.8/4.5 times higher than gated
CD44lo cells. In all three samples, majority of CD44lo cells reside
at G1 phase of the cell cycle.
The data indicate that the CD44hi cells are enriched for S and
G2 phase fractions more than the CD44lo cells indicating slow
growth, quiescence of these cells.
Discussion
Our previous study detected intratumoral heterogeneity in
advance stage of lung cancer by surface marker analysis,
immunohistochemistry (CD44, ALDH, cMET, MDRI) and FACS
(CD44, ALDH, cMET, CD166, MDR-1, uPAR) [5]. This study
extends the earlier observations, and also verifies that subsets of
MPE tumor cells express variable levels of embryonal and
polycomb complex-associated molecular markers. These stem cell
markers have previously been implicated in mediating ‘‘CSC
properties’’, including high tumorigenic potentials. These markers
include (but are clearly not limited to) PTEN, OCT-4, BMI-1,
hTERT, SUZ12, EZH2. In early analyses, we are unable to
associate specific embryonal or polycomb markers with higher
tumorigenic potentials. In the three current MPE primary samples
tested, only one of the CD44hi subsets expressed (M-1) the
Figure 7. Cell cycle parameters of CD44hi and CD44lo cell populations derived from primary cultures of MPE tumors. Representative
FACS analysis of CD44 and PI staining (i and ii) of three samples (A) M-1, (B) M-2 and (C) M-3. The samples were evaluated for their CD44hi (iii) and
CD44lo (iv) and total cells (v, no gate) cell cycle and their G1, S and G2 phase analysis. (D) The results indicate that gated CD44hi population express
high level of S and G2 phase (Sample M-1: S/G2:15.75/72.61; Sample M-2: S/G2:12.03/32.19; Sample M-3: S/G2:6.25/15.17) than the gated CD44lo
population (Sample M-1: S/G2:4.36/1.81; Sample M-2: S/G2:5.18/7.14; Sample M-3: S/G2:3.37/3.32) respectively.
doi:10.1371/journal.pone.0073195.g007
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predicted pattern of candidate CSC-marker expression (lower
PTEN, higher hTERT, SUZ12, EZH2, OCT4 and BMI1) than the
isogenic CD44lo cells. The other two samples (M-2 and M-3) were
quite variable in the expression of markers on this panel. On the
basis of a primary samples (n = 3) that displays a highly variable
expression of markers, we can speculate that it is unlikely that
individual molecular markers will reliably predict the highly
tumorigenic CSC-phenotype in lung cancers.
Whereas our earlier studies focused on demonstrating that
candidate CSC existed in MPE by virtue of surrogate biomarker
expression, this study actually associates the expression of those
biomarkers with behavioral bioassays (colony formation and
tumorigenesis in vivo). We clearly demonstrate that within the
MPE-tumor biospecimen there are tumor cell subsets (CD44hi
cells) with high tumorigenic potentials. Thus, these subsets can
now be characterized as having properties associated with ‘‘cancer
stem cells’’ in three distinct surrogate measures of that property.
Our data also suggest that lung CSC can be distinguished from
non-CSC on the basis of several associated molecular properties
and profiles. Although many additional properties are likely to
emerge with prospective high throughput analyses, this report
provides initial evidence of differences in cell cycle profiles, and in
miRNA expression. Collectively, our studies convincingly demon-
strate that behaviorally aggressive (CSC or tumor initiating cells)
are present within the bulk MPE populations of lung cancer
patients.
The CD44hi cell subsets from different primary tumor cultures
consistently formed tumors in vivo with greater efficiency (Figure 3).
However, these efficiencies and tumor growth kinetics varied quite
dramatically from one sample to another. The surface labeling
intensity of CD44 indicated a better proxy marker for growth
kinetics. The CD44hi cells from the fast growing M-1 sample
displayed higher surface CD44 (MFI = 28243), as compared to the
CD44hi cells from relatively slow growing M-2 sample
(MFI= 12864) (Figure 1E). The CD44hi cells from the M-1 tumor
exhibited a more primitive phenotype (in terms of expected BMI,
hTERT, SUZ12, EZH2, OCT-4 expression), as compared to the
CD44hi cells from the M-2 sample (with only higher hTERT
expression) (Figure 2E). Thus, CD44hi cells from the M-1 sample
were much more efficient at forming in vivo tumors than the
CD44hi cells from M-2 sample. These data suggest that whereas
the CD44hi surface phenotype may commonly predict for more
efficient tumorigenesis in individual tumors, there are likely to be
differences in the molecular signatures that comprise this highly
tumorigenic subset.
As indicated, the main objective of the present study was to
identify and extract the tumor cell subpopulations from MPE that
are responsible for tumor propagation and maintenance, and to
characterize their molecular signature pattern. CD44 had
previously been implicated as a surface marker for CSC as
indicated earlier. Our earlier studies convincingly showed that
almost all the MPE primary tumor cells labeled for surface CD44
(.98%). To distinguish a behaviorally-distinct cell subset amongst
a cell population that contiguously expressed the CD44 surface
marker, we elected to compare tumorigenic potentials of MPE-
tumor cells expressing the highest levels of surface CD44 (CD44hi)
with tumor cells expressing the lowest level of surface CD44
(CD44lo). It was not possible to distinguish these cell subsets simply
on the basis of morphology; i.e.: cells sorted on the basis of CD44hi
and CD44lo are morphologically similar. However, the CD44hi
cells could be clearly distinguished by behavioral properties, such
as high clonal efficiency and high spheroid formation efficiency in
soft agar, the established surrogate in vitro properties of CSC like
cells. Accordingly, this study identifies the CD44hi surface
phenotype as a marker that is associated with high tumorigenic
potentials in individual lung cancers. However, the surface
phenotype may not be associated with a consistent molecular
profile. More importantly, this study does not predict that the
surface CD44hi phenotype is exclusively the cancer cell subset with
higher tumorigenic potentials. Clearly, the surface CD44hi
phenotype is not a homogeneous population. First, the expression
of the CD44 surface marker varies greatly from one tumor to
another. Moreover, surface CD44 expression varies greatly
between individual tumors; the tumor cells that most highly label
for surface CD44 seem to possess greater competence at tumor
formation.
That the CD44hi subset is not a homogeneous cell subset is
suggested by the co-labeling of subsets with additional candidate
CSC markers (e.g.: ALDH). Only a fraction of the CD44hi
subpopulation can be jointly characterized as the CD44hi/
ALDHhi surface phenotype [5]. In order to investigate if there is
a co-relationship between CD44 and other known marker of
CSC/TIC we evaluated one of the most prominent markers,
ALDH, for its expression pattern by immuno-histpathology in the
tissues generated by CD44hi implanted cells in NSG mice and
primary SCC and AC of lung cancer. It is suggested that various
isozymes of ALDH are expressed in different lung cancer cell lines
[31] and ALDH expression is significant for poor prognosis [32].
ALDH, like CD44, may also have a functional role in cancer
progression [33,34]. Our study has shown that only a small
fraction of CD44hi subpopulation can be jointly characterized as
CD44hi/ALDHhi surface phenotype in xenograft tissues and SCC
and AC of the lung cancer.
Chromosomal abnormalities are common in cancer and in lung
cancer losses and/or gains of several chromosomal regions have
also been reported [35]. We were interested to evaluate if
chromosomal abnormalities are also detected in the MPE samples,
as has been reported for lung cancer. To evaluate these
abnormalities we performed G-banded karyotype analysis and
chromosome painting by using Fluorescence In Situ Hybridization
(FISH). Our result indicated hyperploidy and chromosomal
abnormality in all the MPE samples tested. FISH analysis of
1p36 region revealed LOH in two samples and rearrangements of
both 1p/1q regions in the third MPE sample. Thus, indicating
important role of region 1p36 in MPE where miR-34a maps. In
this respect, data presented herein suggest that miR-34a likely
represents a key etiologic factor in contributing to aggressive CSC
phenotypes, and is thus a likely target for curbing the growth
potentials of lung CSC in a subset of lung cancers. Specifically, a
relative loss of miR-34a expression appears to contribute to
aggressive behavioral features of lung CSC, and those features can
be mitigated by exogenous delivery and restoration of miR34a
activity.
Deletion of 1p36 in neuroblastoma has led to identification of a
number of tumor suppressor genes from a 2 Mb region of this
locus. These genes include TP73, CHD5, K1F1B, CAMTA1, and
CASTOR [36]. The p53 induced miRNA-34a also localizes to
this site, and is considered to be a strong candidate tumor
suppressor gene in neurobalstoma and other human cancers.
Studies have shown a suppressive effect on N-myc expression in
neurobalstoma [36] and CD44 in prostate cancer [15], supporting
a role in cancer suppression. In our system the MPE derived
CD44hi cells exhibited low expression of miR-34a.
Mir-34a has been also associated with regulation of cancer stem
cells function in various cancer types such as prostate cancer [15],
pancreatic cancer [37], meduloblastoma [38], glioblastoma [39].
Further, the microRNA miR-34a inhibits prostate cancer stem
cells and metastasis by directly repressing CD44 indicating direct
CD44 and Lung Cancer
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e73195
role of CD44 and mir-34a in cancer development and progression
[15]. In lung cancers, miR-34a is being evaluated as a replacement
therapy candidate; exogenous gene delivery of miR-34a can
reduce tumor growth [40,41].
CSC may maintain themselves at a particular stage of cell cycle
due to differences in cell cycling or activation of checkpoints due to
DNA damage. Recently, Harper et al., [30] showed that CD44hi
cells from both normal and malignant epithelial tissues have
extended G2 cell cycle phase, which is associated with drug
resistance. Our results suggest that even without the use of drug
selection pressure, the CD44hi subset is enriched for cells in the G2
phase of the cell cycle. The CD44lo cells, by contrast, are enriched
for cells in the G1 phase.
The three MPE samples evaluated represent the same stage of
disease progression. However, each specimen is variable both in
terms of histopathological subtype, and grade of differentiation. It is
currently not known whether poorly differentiated cells are
biologically more aggressive, but many have postulated this to
be the case. The M-1 sample is from a younger patient and has
more poorly differentiated cancer cells than sample M-2 and M-3.
In our evaluation, the poorly differentiated cells in this sample
were indeed more tumorigenic, however, this observation needs
additional confirmation. Nevertheless, our pilot data suggests there
is considerable intra-tumoral heterogeneity at an advanced stage
of progression. In addition, despite a similar clinical stage of
disease, there is considerable inter-tumoral heterogeneity between
the clinically isolates, based on the fractional expression of
individual markers and cytopathology. Although our examination
is limited in its scope, these data suggest that understanding the
biological and functional basis of this heterogeneity may enable us
to better understand and develop rational therapeutics for lung
cancer. We are actively seeking resources to expand this scope of
study. However, it is important for us to point out that irrespective
of the underlying histopathological subtype, CD44hi cells are
present in each biospecimen. Perhaps, this observation suggests
that irrespective of the histopathological subtype, the genetic and
epigenetic landscape of CD44hi tumor cells may be similar across
lung cancers. If this hypothesis holds to be true, then we may be in
a position to offer common CD44-biomarker guided therapeutics
across lung cancer subtypes.
In summary, this work substantiates the validity of our lung
cancer MPE model and phenotype-based approach for the
discovery of the molecular bases of functional intratumoral
heterogeneity. This work extends the evidence to support our
proposition that for us to effectively treat cancer, we need to
approach the disease starting from a behavioral phenotype. The
most efficient way for us to accomplish that task is to dissect the
molecular basis of specific properties in behaviorally distinct cell
subsets of individual tumors [42].
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